PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-2.68%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-2.79%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
1.20%
EPS growth 0-5% – Weak but still positive. Howard Marks would remain cautious, suspecting limited pricing power or cost pressures.
2.99%
Diluted EPS growth 0-5% – Minimal improvement. Howard Marks would remain cautious about further dilution or flat net income.
3.80%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
6.10%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
35.18%
OCF growth above 20% – Exceptional cash generation improvement. Warren Buffett might see if the net margin also rises in tandem.
35.60%
FCF growth above 20% – Very attractive to value investors. Warren Buffett would check if capital expenditures remain sensible to maintain this level.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13691.29%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
29.84%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
58.26%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
-7976.92%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
76.35%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
62.71%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
1259.19%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
224.33%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
-84.52%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-26.68%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D growth 20-30% – High. Howard Marks questions ROI unless the pipeline is robust or near commercialization.
-32.93%
Shrinking SG&A can raise profits short term, but might risk cutting key growth drivers. Benjamin Graham sees if this is sustainable.